LAS VEGAS, Oct. 12, 2011 (GLOBE NEWSWIRE) -- Skinvisible, Inc. (OTCQB:SKVI) (OTCBB:SKVI) is pleased to announce that its DermSafe® Hand Sanitizing Lotion has received the "Seal of Approval" from the Dermatology Review Panel™ ("DRP"). DRP is an independent panel of dermatologists that reviews scientific data for non-prescription products in order to authenticate a product's claims.
DRP dermatologists evaluated Skinvisible's scientific data and validated the following claims for DermSafe Hand Sanitizer: DermSafe is alcohol-free, it offers protection from harmful bacteria, it resists wash-off and it provides a moisture barrier for the hands. DermSafe, marketed by Alto Pharmaceuticals in Canada, will soon display the DRP Seal on its promotional materials and packaging.
Claims made by over-the-counter products can be confusing to the consumer so the DRP program was formed to provide an arms-length review of a product's scientific data in support of its claims. The DRP Seal of Approval helps consumers and medical professionals easily identify products that meet the panel's approval standards. The Dermatology Review Panel is comprised of key dermatologists from across Canada. These physicians were selected based on their expertise in skin care, geographical diversity and dedication to the mission of this program. See www.dermatologyreviewpanel.ca.
"With the flu season upon us, it is important that consumers have independent information regarding products offering protection from germs," said Dr. Richard Thomas, dermatologist on the Dermatology Review Panel. "DermSafe Hand Sanitizer is a product that has successfully completed a vigorous scientific review and has earned the DRP endorsement by an independent panel of dermatologists."
"We are pleased that our DermSafe Hand Sanitizer has been recommended by the Dermatology Review Panel," said Mr. Terry Howlett, President and CEO of Skinvisible. "We have invested substantially into research and studies to ensure that we have compelling scientific data to support DermSafe's claims." He added, "We expect that other Skinvisible products formulated with the Invisicare technology will also receive this impressive distinction in the near future."
About Alto Pharmaceuticals
Alto Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of unique products for maintaining a healthy lifestyle and improving quality of life. Alto's areas of interest include Dermatology and Skin Care, Infectious Disease and Wound Care, and the company is dedicated to bringing physicians, patients and consumers unique pharmaceutical products and devices. www.altopharma.com
About Invisicare
Invisicare is Skinvisible's patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. It is a combination of hydrophilic and hydrophobic polymers that hold active ingredients on the skin for extended periods of time resisting both wash off and perspiration. Invisicare can control the release of actives, reduce the amount of actives used and also reduce irritation. It is non-occlusive and allows for normal skin respiration while protecting against environmental irritants. www.invisicare.com
About Skinvisible Pharmaceuticals, Inc.
Skinvisible Pharmaceuticals is a research-and-development company whose primary business objective is to license its proprietary formulations with Invisicare to pharmaceutical and cosmeceutical companies as well as assisting companies in enhancing their existing skin care products. Skinvisible has thirty-six products developed and ready for licensing including prescription, over-the-counter and cosmetic formulations. Skinvisible receives a combination of research and development fees, upfront license fees, and ongoing royalties for the life of the Invisicare patent. Skinvisible's value also lies in its ability to continually generate new IP on dermatology and medical products formulated with Invisicare. www.skinvisible.com
Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10K for the quarter ending June 30, 2011).